Active Pharmaceutical Ingredient CDMO Market Size, Share & Trends Analysis Report By Product (Traditional API, HP-API, Biologics) By Synthesis (Synthetic, Biotech), By Drug (Innovative, Generics), By Application, By Workflow, By Region, And Segment Foreca
Description
Active Pharmaceutical Ingredient CDMO Market Summary
The global active pharmaceutical ingredient CDMO market size was estimated at USD 107.21 billion in 2024 and is projected to reach USD 209.85 billion by 2033, growing at a CAGR of 7.85% from 2025 to 2033. The market is driven due to the increasing demand for scalable and cost-efficient drug development solutions, growing outsourcing trends among pharmaceutical companies to reduce operational costs and focus on core competencies, and increasing R&D activities in specialty and complex APIs.
Moreover, the growing biosimilars and biologics segment, increasing prevalence of chronic diseases, patent expirations of blockbuster drugs, and advancements in manufacturing technologies such as continuous manufacturing and high-potency APIs are further contributing to the industry growth. In addition, several pharmaceutical and biotechnology companies are increasingly outsourcing their API manufacturing services to CDMOs, which is also one of the major factors contributing to market growth. The increasing complexity of drug molecules and the cost advantages offered by CDMOs are the major contributors to the shift from in-house capabilities to outsourcing. Furthermore, the increasing prevalence of chronic diseases globally has intensified the demand for innovative therapies, further pushing the CDMOs to focus on large-scale production, faster development, and regulatory compliance.
Furthermore, increasing pipelines of biologics and biosimilars and a growing demand for HPAPIs contribute to the increasing opportunities. CDMOs have higher levels of expertise and advanced technologies, making them the preferred choice for biotechnology and pharmaceutical companies looking for scalable, compliant, and efficient manufacturing solutions. Moreover, patent expirations of branded and blockbuster drugs are boosting the demand for generic APIs. Thus, these factors are changing the market's competitive landscape, further contributing to the market growth.
Global Active Pharmaceutical Ingredient CDMO Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global active pharmaceutical ingredient CDMO market report based on product, synthesis, drug, application, workflow, and region:
The global active pharmaceutical ingredient CDMO market size was estimated at USD 107.21 billion in 2024 and is projected to reach USD 209.85 billion by 2033, growing at a CAGR of 7.85% from 2025 to 2033. The market is driven due to the increasing demand for scalable and cost-efficient drug development solutions, growing outsourcing trends among pharmaceutical companies to reduce operational costs and focus on core competencies, and increasing R&D activities in specialty and complex APIs.
Moreover, the growing biosimilars and biologics segment, increasing prevalence of chronic diseases, patent expirations of blockbuster drugs, and advancements in manufacturing technologies such as continuous manufacturing and high-potency APIs are further contributing to the industry growth. In addition, several pharmaceutical and biotechnology companies are increasingly outsourcing their API manufacturing services to CDMOs, which is also one of the major factors contributing to market growth. The increasing complexity of drug molecules and the cost advantages offered by CDMOs are the major contributors to the shift from in-house capabilities to outsourcing. Furthermore, the increasing prevalence of chronic diseases globally has intensified the demand for innovative therapies, further pushing the CDMOs to focus on large-scale production, faster development, and regulatory compliance.
Furthermore, increasing pipelines of biologics and biosimilars and a growing demand for HPAPIs contribute to the increasing opportunities. CDMOs have higher levels of expertise and advanced technologies, making them the preferred choice for biotechnology and pharmaceutical companies looking for scalable, compliant, and efficient manufacturing solutions. Moreover, patent expirations of branded and blockbuster drugs are boosting the demand for generic APIs. Thus, these factors are changing the market's competitive landscape, further contributing to the market growth.
Global Active Pharmaceutical Ingredient CDMO Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global active pharmaceutical ingredient CDMO market report based on product, synthesis, drug, application, workflow, and region:
- Product Outlook (Revenue, USD Billion, 2021 - 2033)
- Traditional Active Pharmaceutical Ingredient (Traditional API)
- Highly Potent Active Pharmaceutical Ingredient (HP-API)
- Biologics
- Synthesis Outlook (Revenue, USD Billion, 2021 - 2033)
- Synthetic
- Biotech
- Drug Outlook (Revenue, USD Billion, 2021 - 2033)
- Innovative
- Generics
- Workflow Outlook (Revenue, USD Billion, 2021 - 2033)
- Clinical
- Commercial
- Application Outlook (Revenue, USD Billion, 2021 - 2033)
- Oncology
- Hormonal
- Glaucoma
- Cardiovascular disease
- Diabetes
- Others
- Regional Outlook (Revenue, USD Billion, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Norway
- Sweden
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait
- Oman
- Qatar
Table of Contents
150 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR’s internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Value chain based analysis (Model 2)
- 1.7.3. Multivariate Analysis (Model 3)
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Landscape Insights
- Chapter 3. Active Pharmaceutical Ingredient CDMO Market: Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Ancillary Market Outlook
- 3.2. Active Pharmaceutical Ingredient CDMO Market Dynamics
- 3.2.1. Market Driver Impact Analysis
- 3.2.2. Market Restraint Analysis
- 3.2.3. Market Opportunities
- 3.3. Technological Landscape
- 3.4. Pricing Model Analysis
- 3.5. Tariff Impact Analysis
- 3.6. Supply Chain Analysis
- 3.7. Market Analysis Tools
- 3.7.1. Porter’s Five Forces Analysis
- 3.7.2. PESTEL by SWOT Analysis
- Chapter 4. Active Pharmaceutical Ingredient CDMO Market: Product Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Global Active Pharmaceutical Ingredient CDMO Market Product Movement Analysis
- 4.3. Global Active Pharmaceutical Ingredient CDMO Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Billion)
- 4.4. Traditional Active Pharmaceutical Ingredient (Traditional API)
- 4.4.1. Traditional Active Pharmaceutical Ingredient (Traditional API) Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 4.5. Highly Potent Active Pharmaceutical Ingredient (HP-API)
- 4.5.1. Highly Potent Active Pharmaceutical Ingredient (HP-API) Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 4.6. Biologics
- 4.6.1. Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- Chapter 5. Active Pharmaceutical Ingredient CDMO Market: Synthesis Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Global Active Pharmaceutical Ingredient CDMO Market Synthesis Movement Analysis
- 5.3. Global Active Pharmaceutical Ingredient CDMO Market Size & Trend Analysis, by Synthesis, 2021 to 2033 (USD Billion)
- 5.4. Synthetic
- 5.4.1. Synthetic Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 5.5. Biotech
- 5.5.1. Biotech Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- Chapter 6. Active Pharmaceutical Ingredient CDMO Market: Drug Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Global Active Pharmaceutical Ingredient CDMO Market Drug Movement Analysis
- 6.3. Global Active Pharmaceutical Ingredient CDMO Market Size & Trend Analysis, by Drug, 2021 to 2033 (USD Billion)
- 6.4. Innovative
- 6.4.1. Innovative Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 6.5. Generics
- 6.5.1. Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- Chapter 7. Active Pharmaceutical Ingredient CDMO Market: Application Estimates & Trend Analysis
- 7.1. Segment Dashboard
- 7.2. Global Active Pharmaceutical Ingredient CDMO Market Application Movement Analysis
- 7.3. Global Active Pharmaceutical Ingredient CDMO Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Billion)
- 7.4. Oncology
- 7.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.5. Hormonal
- 7.5.1. Hormonal Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.6. Glaucoma
- 7.6.1. Glaucoma Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.7. Cardiovascular disease
- 7.7.1. Cardiovascular disease Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.8. Diabetes
- 7.8.1. Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.9. Others
- 7.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- Chapter 8. Active Pharmaceutical Ingredient CDMO Market: Workflow Estimates & Trend Analysis
- 8.1. Segment Dashboard
- 8.2. Global Active Pharmaceutical Ingredient CDMO Market Workflow Movement Analysis
- 8.3. Global Active Pharmaceutical Ingredient CDMO Market Size & Trend Analysis, by Workflow, 2021 to 2033 (USD Billion)
- 8.4. Clinical
- 8.4.1. Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5. Commercial
- 8.5.1. Commercial Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- Chapter 9. Active Pharmaceutical Ingredient CDMO Market: Regional Estimates & Trend Analysis by Product, Synthesis, Drug, Application, Workflow
- 9.1. Regional Market Dashboard
- 9.2. Global Regional Market Snapshot
- 9.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
- 9.4. North America
- 9.4.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.4.2. U.S.
- 9.4.2.1. Key Country Dynamics
- 9.4.2.2. Competitive Scenario
- 9.4.2.3. Regulatory Framework
- 9.4.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.4.3. Canada
- 9.4.3.1. Key Country Dynamics
- 9.4.3.2. Competitive Scenario
- 9.4.3.3. Regulatory Framework
- 9.4.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.4.4. Mexico
- 9.4.4.1. Key Country Dynamics
- 9.4.4.2. Competitive Scenario
- 9.4.4.3. Regulatory Framework
- 9.4.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.5. Europe
- 9.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.5.2. UK
- 9.5.2.1. Key Country Dynamics
- 9.5.2.2. Competitive Scenario
- 9.5.2.3. Regulatory Framework
- 9.5.2.4. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.5.3. Germany
- 9.5.3.1. Key Country Dynamics
- 9.5.3.2. Competitive Scenario
- 9.5.3.3. Regulatory Framework
- 9.5.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.5.4. France
- 9.5.4.1. Key Country Dynamics
- 9.5.4.2. Competitive Scenario
- 9.5.4.3. Regulatory Framework
- 9.5.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.5.5. Italy
- 9.5.5.1. Key Country Dynamics
- 9.5.5.2. Competitive Scenario
- 9.5.5.3. Regulatory Framework
- 9.5.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.5.6. Spain
- 9.5.6.1. Key Country Dynamics
- 9.5.6.2. Competitive Scenario
- 9.5.6.3. Regulatory Framework
- 9.5.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.5.7. Denmark
- 9.5.7.1. Key Country Dynamics
- 9.5.7.2. Competitive Scenario
- 9.5.7.3. Regulatory Framework
- 9.5.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.5.8. Sweden
- 9.5.8.1. Key Country Dynamics
- 9.5.8.2. Competitive Scenario
- 9.5.8.3. Regulatory Framework
- 9.5.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.5.9. Norway
- 9.5.9.1. Key Country Dynamics
- 9.5.9.2. Competitive Scenario
- 9.5.9.3. Regulatory Framework
- 9.5.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.6. Asia Pacific
- 9.6.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.6.2. Japan
- 9.6.2.1. Key Country Dynamics
- 9.6.2.2. Competitive Scenario
- 9.6.2.3. Regulatory Framework
- 9.6.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.6.3. China
- 9.6.3.1. Key Country Dynamics
- 9.6.3.2. Competitive Scenario
- 9.6.3.3. Regulatory Framework
- 9.6.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.6.4. India
- 9.6.4.1. Key Country Dynamics
- 9.6.4.2. Competitive Scenario
- 9.6.4.3. Regulatory Framework
- 9.6.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.6.5. Australia
- 9.6.5.1. Key Country Dynamics
- 9.6.5.2. Competitive Scenario
- 9.6.5.3. Regulatory Framework
- 9.6.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.6.6. South Korea
- 9.6.6.1. Key Country Dynamics
- 9.6.6.2. Competitive Scenario
- 9.6.6.3. Regulatory Framework
- 9.6.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.6.7. Thailand
- 9.6.7.1. Key Country Dynamics
- 9.6.7.2. Competitive Scenario
- 9.6.7.3. Regulatory Framework
- 9.6.7.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.7. Latin America
- 9.7.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.7.2. Brazil
- 9.7.2.1. Key Country Dynamics
- 9.7.2.2. Competitive Scenario
- 9.7.2.3. Regulatory Framework
- 9.7.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.7.3. Argentina
- 9.7.3.1. Key Country Dynamics
- 9.7.3.2. Competitive Scenario
- 9.7.3.3. Regulatory Framework
- 9.7.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.8. MEA
- 9.8.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.8.2. South Africa
- 9.8.2.1. Key Country Dynamics
- 9.8.2.2. Competitive Scenario
- 9.8.2.3. Regulatory Framework
- 9.8.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.8.3. Saudi Arabia
- 9.8.3.1. Key Country Dynamics
- 9.8.3.2. Competitive Scenario
- 9.8.3.3. Regulatory Framework
- 9.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.8.4. UAE
- 9.8.4.1. Key Country Dynamics
- 9.8.4.2. Competitive Scenario
- 9.8.4.3. Regulatory Framework
- 9.8.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.8.5. Kuwait
- 9.8.5.1. Key Country Dynamics
- 9.8.5.2. Competitive Scenario
- 9.8.5.3. Regulatory Framework
- 9.8.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.8.6. Oman
- 9.8.6.1. Key Country Dynamics
- 9.8.6.2. Competitive Scenario
- 9.8.6.3. Regulatory Framework
- 9.8.6.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.8.7. Qatar
- 9.8.7.1. Key Country Dynamics
- 9.8.7.2. Competitive Scenario
- 9.8.7.3. Regulatory Framework
- 9.8.7.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- Chapter 10. Competitive Landscape
- 10.1. Company Categorization
- 10.1.1. Market Leaders
- 10.1.2. Emerging Players
- 10.2. Active Pharmaceutical Ingredient CDMO Market Share Analysis, 2024
- 10.3. Company Profiles
- 10.3.1. Cambrex Corporation
- 10.3.1.1. Company Overview
- 10.3.1.2. Financial Performance
- 10.3.1.3. Product/Service Benchmarking
- 10.3.1.4. Strategic Initiatives
- 10.3.2. Recipharm AB
- 10.3.2.1. Company Overview
- 10.3.2.2. Financial Performance
- 10.3.2.3. Product/Service Benchmarking
- 10.3.2.4. Strategic Initiatives
- 10.3.3. Thermo Fisher Scientific Inc.
- 10.3.3.1. Company Overview
- 10.3.3.2. Financial Performance
- 10.3.3.3. Product/Service Benchmarking
- 10.3.3.4. Strategic Initiatives
- 10.3.4. CordenPharma International
- 10.3.4.1. Company Overview
- 10.3.4.2. Financial Performance
- 10.3.4.3. Product/Service Benchmarking
- 10.3.4.4. Strategic Initiatives
- 10.3.5. Samsung Biologics
- 10.3.5.1. Company Overview
- 10.3.5.2. Financial Performance
- 10.3.5.3. Product/Service Benchmarking
- 10.3.5.4. Strategic Initiatives
- 10.3.6. Lonza
- 10.3.6.1. Company Overview
- 10.3.6.2. Financial Performance
- 10.3.6.3. Product/Service Benchmarking
- 10.3.6.4. Strategic Initiatives
- 10.3.7. Catalent, Inc.
- 10.3.7.1. Company Overview
- 10.3.7.2. Financial Performance
- 10.3.7.3. Product/Service Benchmarking
- 10.3.7.4. Strategic Initiatives
- 10.3.8. Siegfried Holding AG
- 10.3.8.1. Company Overview
- 10.3.8.2. Financial Performance
- 10.3.8.3. Product/Service Benchmarking
- 10.3.8.4. Strategic Initiatives
- 10.3.9. Piramal Pharma Solutions
- 10.3.9.1. Company Overview
- 10.3.9.2. Financial Performance
- 10.3.9.3. Product/Service Benchmarking
- 10.3.9.4. Strategic Initiatives
- 10.3.10. Boehringer Ingelheim International GmbH
- 10.3.10.1. Company Overview
- 10.3.10.2. Financial Performance
- 10.3.10.3. Product/Service Benchmarking
- 10.3.10.4. Strategic Initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.